All In Biotech

Drug Trial Radar · NCT05905055

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection Due to Carbapenem Resistant Enterobacterales

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Sep 22, 2023

Primary completion

Sep 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Meiji Seika Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis
  • Hospital-acquired Bacterial Pneumonia
  • Ventilator-associated Bacterial Pneumonia
  • Complicated Intra-abdominal Infection

Interventions

  • co-administration of cefepime and nacubactamDrug

    2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes

  • co-administration of aztreonam and nacubactamDrug

    2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes

  • BATDrug

    Dosage of BAT will be based per site's standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the proportion of patients with overall treatment success at TOC across all infection types (ie, cUTI, AP, HABP, VABP, and cIAI), which is a composite endpoint derived from the efficacy outcomes of each infection type.Time frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]

Locations

54 sites in 14 countries. Site status is shown where the registry gives one.

  • Meiji Research Site

    Changsha, China

  • Meiji Research Site

    Chongqing, China

  • Meiji Research Site

    Fuyang, China

  • Meiji Research Site

    Guangzhou, China

  • Meiji Research Site

    Hangzhou, China

  • Meiji Research Site

    Hefei, China

  • Meiji Research Site

    Nanjing, China

  • Meiji Research Site

    Nanning, China

  • Meiji Research Site

    Quanzhou, China

  • Meiji Research Site

    Shanghai, China

  • Meiji Research Site

    Shenzhen, China

  • Meiji Research Site

    Shijiazhuang, China

  • Meiji Research Site

    Wuxi, China

  • Meiji Research Site

    Xuzhou, China

  • Meiji Research Site

    Zagreb, Croatia

  • Meiji Research Site

    Kyjov, Czechia

  • Meiji Research Site

    Limoges, France

  • Meiji Research Site

    Nîmes, France

  • Meiji Research Site

    Paris, France

  • Meiji Research Site

    Strasbourg, France

  • Meiji Research Site

    Kutaisi, Georgia

  • Meiji Research Site

    Tbilisi, Georgia

  • Meiji Research Site

    Zestaponi, Georgia

  • Meiji Research Site

    Athens, Greece

  • Meiji Research Site

    Be’er Ya‘aqov, Israel

  • Meiji Research Site

    Ramat Gan, Israel

  • Meiji Research Site

    Tel Aviv, Israel

  • Meiji Research Site

    Hiroshima, Japan

  • Meiji Research Site

    Kanazawa, Japan

  • Meiji Research Site

    Nagasaki, Japan

  • Meiji Research Site

    Nankoku, Japan

  • Meiji Research Site

    Ōta-ku, Japan

  • Meiji Research Site

    Shinjuku-ku, Japan

  • Meiji Research Site

    Toyoake, Japan

  • Meiji Research Site

    Nankoku, Kochi, Japan

  • Meiji Research Site

    Daugavpils, Latvia

  • Meiji Research Site

    Liepāja, Latvia

  • Meiji Research Site

    Riga, Latvia

  • Meiji Research Site

    Valmiera, Latvia

  • Meiji Research Site

    Nitra, Slovakia

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.